Search - tctmd.com

Displaying 1 - 20 of 255

Sort: Relevancy | Date

News Conference News ACC 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

Todd Neale

April 02, 2026

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

Presentation ACC 2026

Essence-TIMI 73b CCTA Trial: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis

Presenter: Nicholas Marston

March 30, 2026

Presentation ACC 2026

IVUS or angiography guidance for PCI in complex coronary bifurcation lesions: The DKCRUSH VIII Trial

Presenter: Shao-Liang Chen

March 30, 2026

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

L.A. McKeown

March 29, 2026

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Presentation ACC 2026

Controlled trial of High-risk coronary Intervention with Percutaneous left ventricular unloading (CHIP-BCIS3)

Presenter: Divaka Perera

March 29, 2026

Presentation ACC 2026

Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina – (ORBITA-CTO) A randomized, placebo-controlled trial

Presenter: Sarosh Khan

March 29, 2026

Presentation ACC 2026

SPIRonolactone In the Treatment of Heart Failure

Presenter: Frank Edelmann

March 29, 2026

Presentation ACC 2026

Deferral of PCI in Patients Undergoing TAVI (PRO-TAVI): an Investigator-Initiated, Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial

Presenter: Michiel Voskuil

March 29, 2026

Presentation ACC 2026

Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment: The ALL-RISE Randomized Trial

Presenter: Ajay J. Kirtane

March 29, 2026

Presentation ACC 2026

Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR guided revascularization: the FAST III Trial

Presenter: Joost Daemen

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2026

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

Michael O'Riordan

March 28, 2026

Presentation ACC 2026

The STEMI Door to Unload Trial (STEMI-DTU)

Presenter: Gregg Stone

March 28, 2026

Presentation ACC 2026

Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial

Presenter: Byeong-Keuk Kim

March 28, 2026

Advertisement

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Essence-TIMI 73b CCTA Trial: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis

IVUS or angiography guidance for PCI in complex coronary bifurcation lesions: The DKCRUSH VIII Trial

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Controlled trial of High-risk coronary Intervention with Percutaneous left ventricular unloading (CHIP-BCIS3)

Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina – (ORBITA-CTO) A randomized, placebo-controlled trial

SPIRonolactone In the Treatment of Heart Failure

Deferral of PCI in Patients Undergoing TAVI (PRO-TAVI): an Investigator-Initiated, Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial

Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment: The ALL-RISE Randomized Trial

Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR guided revascularization: the FAST III Trial

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

The STEMI Door to Unload Trial (STEMI-DTU)

Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content